Stock analysts at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock. VBI Vaccines Stock Performance Shares of VBIV stock opened at $0.63 on Thursday. VBI Vaccines has a 52-week low […]